Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa–Associated Squamous Cell Carcinoma
Abstract
Squamous cell carcinoma (SCC) of the skin is the leading cause of death in patients with the severe generalized form of the genetic disease recessive dystrophic epidermolysis bullosa (RDEB). Although emerging data are identifying why patients suffer this fatal complication, therapies for treatment of RDEB SCC are in urgent need.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2019
- Source ID
- 10.1158/1078-0432.ccr-18-2661
Entities
People
- Alain Hovnanian
- Andrew P South
- Celine Pourreyron
- Christian A. Brown Iv
- Christina Gruber
- Cristina Has
- Elham Rashidghamat
- Francis Palisson
- Ignacia Fuentes
- Jemima E. Mellerio
- Johann W. Bauer
- John A. Mcgrath
- Josefina Piñón Hofbauer
- Julio C Salas-Alanis
- Marco Prisco
- Mehdi Farshchian
- Michael Lawler
- Michael Warkala
- Sheila Wright
- Stephen A. Watt
- Velina S. Atanasova
Organizations
- Congressionally Directed Medical Research Programs
- King's College London
- National Cancer Institute
- Thomas Jefferson University
- Universidad del Desarrollo
- University of Dundee
- University of Freiburg